Portal de Periódicos da CAPES

p53 ACCUMULATION ASSOCIATED WITH bcl-2, THE PROLIFERATION MARKER MIB-1 AND SURVIVAL IN PATIENTS WITH PROSTATE CANCER SUBJECTED TO WATCHFUL WAITING

2000; Lippincott Williams & Wilkins; Volume: 164; Issue: 3 Part 1 Linguagem: Inglês

10.1016/s0022-5347(05)67288-6

1527-3792

Michael Borre, Birgitte Stausbøl‐Grøn, Jens Overgaard,

Prostate Cancer Treatment and Research

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Sep 2000p53 ACCUMULATION ASSOCIATED WITH bcl-2, THE PROLIFERATION MARKER MIB-1 AND SURVIVAL IN PATIENTS WITH PROSTATE CANCER SUBJECTED TO WATCHFUL WAITING MICHAEL BORRE, BIRGITTE STAUSBØL-GRØN, and JENS OVERGAARD MICHAEL BORREMICHAEL BORRE , BIRGITTE STAUSBØL-GRØNBIRGITTE STAUSBØL-GRØN , and JENS OVERGAARDJENS OVERGAARD View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)67288-6AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We describe the association of p53 nuclear protein accumulation with bcl-2 expression, tumor cell proliferation and clinical outcome in a prostate cancer population undergoing watchful waiting. Materials and Methods: Immunohistochemical staining for p53 was semiquantitatively scored in archival formalin fixed, paraffin embedded tumor tissue obtained at diagnosis in 221 patients with prostate cancer. At a median of 15 years followup was nearly complete. Eventually 57% of the patients died of prostate cancer. Results: p53 Immunohistochemical staining was heterogeneous but in all cases at least clusters of tumor cells had nuclear staining for p53. The percent of p53 immunoreactive tumor cells was scored as 0 to 4+ in p53 positive hot spots. p53 immunoreactivity correlated with clinical stage and histopathological grade (p = 0.003 and 0.009, respectively). When dichotomized into low (0% to 50%) and high (51% to 100%) immunoreactivity groups of 40 and 181 patients, respectively, p53 accumulation was significantly associated with disease specific survival in the study population overall (p <0.0001) and in the 125 with clinically localized disease (p = 0.0002). p53 Immunoreactivity was significantly (p <0.001) associated with the proliferation marker MIB-1 (median value 10.3, range 0 to 46.1) but insignificantly (p = 0.8) correlated with bcl-2 expression (52% positive). However, patients with combined favorable MIB-1 and bcl-2 status were stratified into significant (p = 0.02) prognostic groups by p53 immunohistochemical status. Multivariate analysis revealed that p53 immunoreactivity was a significant prognostic factor in patients with clinically localized prostate cancer (p <0.0001). Conclusions: p53 Nuclear protein accumulation detected by immunohistochemical study was an independent adverse prognostic factor in patients with prostate cancer undergoing watchful waiting. References 1 : Bericht über die Zählung der am 1. April 1908 in Dänemark in ärztlicher Behandlung gewesenen Krebskranken. Z Krebsforschung1910; 9: 275. Google Scholar 2 : The dilemma of prostate cancer. A growing human and economic burden irrespective of treatment strategies. Acta Oncol1997; 36: 681. Google Scholar 3 : Prediction of cancer incidence in the Nordic countries up to the years 2000 and 2010. APMIS1993; 38: 64. Google Scholar 4 : Prediction of cancer mortality in the Nordic countries up to the years 2000 and 2010, on the basis of relative survival analysis. A collaborative study of the five Nordic Cancer Registries. APMIS1995; 49: 1. Google Scholar 5 : The natural history of prostate carcinoma based on a Danish population treated with no intent to cure. Cancer1997; 80: 917. Google Scholar 6 : Trends in prostate cancer care in the United States, 1974–1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin1993; 43: 83. Google Scholar 7 : Mutant p53: the commonest genetic abnormality in human cancer?. J Pathol1990; 162: 5. Google Scholar 8 : Abberant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene1991; 6: 1699. Google Scholar 9 : Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature1991; 349: 802. Google Scholar 10 : Localization of the gene for human p53 tumour antigen to band 17p13. Nature1986; 320: 84. Google Scholar 11 : The p53 tumour suppressor gene. Nature1991; 351: 453. Crossref, Medline, Google Scholar 12 : p53 function and dysfunction. Cell1992; 70: 523. Google Scholar 13 : p53, guardian of the genome. Nature1992; 358: 15. Google Scholar 14 : p53-mediated cell death: relationship to cell cycle control. Mol Cell Biol1993; 13: 1415. Google Scholar 15 : An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods1992; 151: 237. Google Scholar 16 : p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst1993; 85: 1657. Google Scholar 17 : Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol1995; 26: 106. Google Scholar 18 : bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer1996; 74: 1258. Google Scholar 19 : p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res1995; 1: 1295. Google Scholar 20 : Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated localized prostate cancer. J Urol1996; 156: 1511. Link, Google Scholar 21 : Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Urology1996; 47: 366. Google Scholar 22 : Prognostic significance of bcl-2 in clinically localized prostate cancer. Am J Pathol1996; 148: 1557. Google Scholar 23 : Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res1996; 2: 399. Google Scholar 24 : The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol1997; 79: 190. Google Scholar 25 : Combined analysis with bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma. J Urol1997; 158: 2278. Link, Google Scholar 26 : p53, bcl2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol1997; 158: 131. Link, Google Scholar 27 : Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer1998; 82: 168. Crossref, Medline, Google Scholar 28 : Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol1999; 161: 1238. Link, Google Scholar 29 : BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol1999; 162: 12. Link, Google Scholar 30 : p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer1999; 85: 1293. Google Scholar 31 : p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol1999; 162: 2040. Link, Google Scholar 32 : Prostatic carcinoma: a multivariate analysis of prognostic factors. Br J Cancer1994; 69: 924. Google Scholar 33 : p53 immunoreactivity as prognostic marker for cancer-specific survival in prostate cancer. Eur Urol1996; 30: 65. Crossref, Medline, Google Scholar 34 : An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res1996; 56: 3814. Medline, Google Scholar 35 : Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer1972; 26: 239. Google Scholar 36 : Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly. Prostate Cancer Prostatic Dis1998; 5: 268. Google Scholar 37 : Tumor cell proliferation and survival in patients with prostate cancer followed expectantly. J Urol1998; 159: 1609. Link, Google Scholar 38 : Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol1992; 168: 357. Google Scholar 39 : Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature1990; 348: 334. Google Scholar 40 : Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst1996; 88: 1054. Google Scholar 41 : Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique. Cancer1972; 30: 5. Google Scholar 42 : Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer1998; 78: 940. Google Scholar 43 : Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. Prostate1998; 37: 223. Google Scholar 44 : The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker?. Urology1996; 48: 971. Google Scholar 45 : p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res1994; 54: 3752. Google Scholar 46 : Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer1994; 69: 26. Google Scholar 47 : Assessing p53 status in breast cancer prognosis: where should you put the thermometer if you think your p53 is sick?. J Natl Cancer Inst1996; 88: 141. Google Scholar 48 : p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential markers in human prostatic cancer. Urology1996; 48: 261. Google Scholar 49 : Protein expression of p53, bcl-2, and Ki-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery1996; 120: 159. Crossref, Medline, Google Scholar From the Danish Cancer Society, Departments of Experimental Clinical Oncology and Urology, Aarhus University Hospital, Aarhus, Denmark© 2000 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byAbaza R, Diaz L, Laskin W and Pins M (2018) Prognostic Value of DNA Ploidy, bcl-2 and p53 in Localized Prostate Adenocarcinoma Incidentally Discovered at Transurethral ProstatectomyJournal of Urology, VOL. 176, NO. 6, (2701-2705), Online publication date: 1-Dec-2006.Martin R, Gunnell D, Hamdy F, Neal D, Lane A and Donovan J (2018) Continuing Controversy Over Monitoring Men With Localized Prostate Cancer: A Systematic Review of Programs in the Prostate Specific Antigen EraJournal of Urology, VOL. 176, NO. 2, (439-449), Online publication date: 1-Aug-2006. Volume 164Issue 3 Part 1September 2000Page: 716-721 Advertisement Copyright & Permissions© 2000 by American Urological Association, Inc.Keywordsgenes, bcl-2prostatic neoplasmsprostategenes, p53tumor markers, biologicalMetricsAuthor Information MICHAEL BORRE More articles by this author BIRGITTE STAUSBØL-GRØN More articles by this author JENS OVERGAARD More articles by this author Expand All Advertisement PDF downloadLoading ...